Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Down 12.6% in January

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 6,170,000 shares, a drop of 12.6% from the January 15th total of 7,060,000 shares. Based on an average trading volume of 5,290,000 shares, the days-to-cover ratio is presently 1.2 days.

Applied DNA Sciences Trading Down 2.4 %

NASDAQ APDN traded down $0.00 during trading on Friday, reaching $0.17. 3,022,747 shares of the company’s stock were exchanged, compared to its average volume of 1,898,681. Applied DNA Sciences has a fifty-two week low of $0.12 and a fifty-two week high of $14.40. The company’s fifty day simple moving average is $0.19 and its 200-day simple moving average is $0.52.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Thursday, February 13th. The technology company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.24). Applied DNA Sciences had a negative return on equity of 111.18% and a negative net margin of 203.76%. As a group, analysts predict that Applied DNA Sciences will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Applied DNA Sciences

A hedge fund recently raised its stake in Applied DNA Sciences stock. Geode Capital Management LLC lifted its stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 291.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 417,485 shares of the technology company’s stock after acquiring an additional 310,749 shares during the period. Geode Capital Management LLC owned 0.76% of Applied DNA Sciences worth $85,000 at the end of the most recent reporting period. 22.22% of the stock is currently owned by institutional investors.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.